INVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022 2 This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strat

INVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022

2 This presentation contains forward-looking statements about PDS Biotechnology Corporation

("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre- clinical and clinical drug development activities and timelines and market opportunities. All

statements other than statements of historical facts included in this presentation are forward-looking statements. The words "anticipates," "may," "can," "plans," "believes," "estimates," "expects," "projects," "intends," "likely," "will,"

"should," "to be," and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could

cause actual results to differ materially from those anticipated. Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption "Risk Factors" in the documents filed

with the Securities and Exchange Commission ("SEC") from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this

presentation to reflect subsequent events or circumstances. Forward Looking Statements

Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious

diseaseVersamune and Infectimune platforms leverage the body's own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious diseaseThree phase 2 oncology clinical trials in progress with

readouts anticipated Q1/Q2Preliminary data released at 2021 ASCO - Checkpoint inhibitor refractory patient survival exceeded alternative checkpoint inhibitor monotherapy treatmentClinical partnerships with Merck, MD Anderson Cancer Center and

National Cancer InstituteComposition patent for lead candidate PDS0101 - protection through October 2037Debt free with approximately $69.7M in cash as of September 30, 2021 Corporate Overview 3

Versamune Oncology Platform

5 More than 40,500 patients were estimated to have been diagnosed last year with HPV16-associated

cancers in the US1, 2HPV vaccination is not expected to impact the rate of HPV-related cancer incidence for decadesExisting immunotherapies cost $150,000+ annually per patient3 1SEER Research Data 1975-2018. 2Martel et al. 2017.

International Journal of Cancer, Worldwide burden of cancer attributable to HPV by site, country and HPV type. 3Hernandez et al. 2018. American Journal of Managed Care Volume 24, Issue 2; Company Research US HPV-associated cancer incidence1,

2 Lead asset PDS0101Designed to treat human papillomavirus (HPV16)-associated cancers, representing a $6B opportunity in the US Head and Neck Cervical Anal Vaginal Vulvar Penile

6 ASCO 2021: Triple combination shows promising durability of potential for anti-cancer efficacy in

HPV16-positive patients PDS0101 + Bintrafusp alfa + M9241 Standard of Care(Checkpoint Inhibitors) HPV16-positive Number of checkpoint inhibitor na ve patients 6 Survival at median of 8 months 100% (6/6) Historical is 7-11

months Number of checkpoint inhibitor refractory patients 12 Survival at median of 8 months 83% (10/12) Historical is 3-4 months Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and

Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. Update: As of December 31, 2021, 37 patients (30 HPV16

positive) have been evaluated with a median survival exceeding 12 months in this populationThe study is still progressing and recruiting and updates will be provided in the future

ASCO 2021 Interim proof-of-concept data suggests targeted CD8+ killer T-cell response induced by

Versamune results in tumor shrinkage 7 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of

Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation, includes both CPI refractory and na ve

patients 67% (12/18) 12% - 24% 0% (0/7)

Versamune is designed to Recruit, Train and Arm T-cells in the body 8 References: Gandhapudi SK, et

al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Smalley Rumfield C et al. 2020.

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612. 1. Recruits T-cells to lymph nodes: 2. Trains T-cells to target tumors 3. Arms T-cells to kill tumor cellsse Versamune

+ Tumor-associated proteins (antigens)

9 Generate the right type and quantity of effective CD8+ killer T-cells Generate potency without

serious systemic side effects Generate memory T-cells, to enhance durability of response Competitve Barrier to Entry:Versamune is designed to promote powerful, CD8+ killer T-cell responses in vivo Versamune -based therapies also show

promising potential to: 70-90% of cancer patients fail check point inhibitor therapy

Strong Pipeline with Industry Leading PartnershipsVersamune -based oncology pipeline is being

developed in partnership with the leaders in immuno-oncology 10 Reference: Data on file.

11 Phase 2: PDS0101 + KEYTRUDA Company-sponsored trial for the treatment of HPV16-positive

metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA (Standard of Care): Anti-PD1 checkpoint

inhibitor (ORR ~20%)PDS0101: Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Group 1: Objective response rate (ORR) as first-line treatment in checkpoint inhibitor (CPI) na ve patientsGroup 2: ORR in

patients who have failed checkpoint inhibitor therapy (CPI refractory) Timing Safety data confirmed and released Q4 2021Preliminary efficacy data anticipated Q1 2022 Trial Partner Confirmation that PDS0101 enhances the therapeutic

benefit of checkpoint inhibitors could expand evaluation of Versamune -based therapies in multiple cancer indications

12 Phase 2: PDS0101 + ChemoradiotherapyInvestigator-led trial evaluating the combination in patients

with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer - Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT - Standard of Care): Cisplatin and radiation therapyPDS0101:

Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Safety, rate of regression and local control in patients with primary tumor 5cm (n=35 patients) Timing Preliminary data anticipated Q2 2022 - Rate

of complete response by PET-CT at 6 months and rate of tumor volume reduction by MRI at 30-40 days from start of treatment Trial Sponsor If successful, this study could support further investigation of Versamune -based immunotherapies in

combination with chemotherapy or CRT to treat multiple cancers

13 13 PDS0102: TARP antigen Greater quantity and quality of Versamune -induced CD8+ killer T-cells

may result in ability to treat TARP positive prostate and breast cancers 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8)CFA - Complete Freund's Adjuvant a highly potent immune activator not used in humans due to potentially

lethal toxicity*Reference: Surveillance Research Program, National Cancer Institute SEER Assumes $150K for annual course of therapy; in line with current immunotherapy treatment PRE-CLINICAL OPTIMIZATION STUDIES1: TARP-Specific T-cell

Induction after 2 injections of PDS0102 Announced license with NCI TARP antigens $40B TARP Total MarketOpportunity*

14 14 PDS0103: MUC1 antigenGreater quantity and quality of Versamune -induced CD8+ killer T-cells may

result in ability to treat MUC1-positive cancers Induced a >10-fold number of polyfunctional (highly potent) MUC1 specific CD8+ T-cells Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model

with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906. $100B MUC1 Total Market Opportunity* *Reference:

Surveillance Research Program, National Cancer Institute SEERAssumes $150K for annual course of therapy; in line with current immunotherapy treatment** Patient and value Asessments have not been adjusted to reflect MUC1-expression, which is

currently unknown by tumor type Reference: Surveillance Research Program, National Cancer Institute SEER* Assumes $150K for annual course of therapy; in line with current immunotherapy treatment

Infectimune Infectious Diseased Platform

PDS Biotech's Infectimune Pipeline Developed in partnership with leaders in infectious

disease 16 Reference: Data on file. *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil ("MCTI")

Universal Flu Announced Option Agreement for license with University of Georgia for universal flu

antigens Preclinical work completeCOVIDAgreement with Farmacore extended through May 2022Scale up and manufacturing currently in process Infectimune Pipeline Update on Infectious Disease 17

Near-Term Milestones

Projected milestones through 2022* *Based on current enrollment and forecast modeling as of January

2022. Subject to change. 4Q22 3Q22 2Q22 1Q22 4Q21 3Q21 2Q21 Preliminary efficacy data from advanced HPV-associated cancer trial (NCI) Interim data from HPV-associated cancer trial (NCI) Preliminary data from ImmunoCerv (MD Anderson)

expected Preliminary data from VERSATILE-002 (KEYTRUDA combo) expected Expected completion of HPV-associated cancer trial (NCI) PDS0101 19 PDS Biotech Funded Clinical Trials Partner Co-Funded Clinical

Trials PDS0102 PDS0103 Planned initiation of Phase 1/2 clinical trial in TARP-related cancers Planned initiation of Phase 1/2 clinical trial in MUC1-related cancers

PDS Biotech ManagementHistorical success in the development and commercialization of leading

pharmaceutical products 20 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet (Liposome Company/ Elan)PEG-Intron (Schering-Plough/ Merck) Frank

Bedu-Addo, PhDChief Executive Officer Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Gregory Conn, PhDChief Scientific Officer >30 years

of translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Lauren V. Wood, MDChief Medical Officer >20 years of financial and

operational leadership roles for life sciences companiesFormer Chief Financial Officer of several publicly traded companies Matthew HillChief Financial Officer

Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious

diseaseVersamune and Infectimune platforms leverage the body's own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious diseaseThree phase 2 oncology clinical trials in progress with

readouts anticipated Q1/Q2Preliminary data released at 2021 ASCO - Checkpoint inhibitor refractory patient survival exceeded alternative checkpoint inhibitor monotherapy treatmentClinical partnerships with Merck, MD Anderson Cancer Center and

National Cancer InstituteComposition patent for lead candidate PDS0101 - protection through October 2037Debt free with approximately $69.7M in cash as of September 30, 2021 Corporate Overview 21

PDS Biotechnology Nasdaq: PDSB Precision Designed Science to Treat Cancer